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In the acute phase of stroke, up to three quarters of patients experience high blood pressure (BP), a phenomenon yet 
understood incompletely.1,2 Guidelines recommend tolerat-
ing a BP up to 220/120 mm Hg, 185/110 mm Hg, and 180/105 
mm Hg in patients in general, before, and after administer-
ing intravenous thrombolysis (IVT) because of the most 
feared complication symptomatic intracerebral hemorrhage 
(SICH).3 Most observational studies found an association 
between higher admission systolic BP (BP
sys
) and worse out-
come describing a distinct U-shaped admission BP
sys
 relation. 
Thereby, a range of 141 to 150 mmHg BP
sys
 yielded best func-
tional outcome at 90 days after stroke.4–8
Even so, clinical trials investigating active BP lowering in 
acute ischemic stroke have not shown an advantage from BP 
intervention neither for safety nor for functional outcome.9–12 
One recent post hoc analysis from a clinical trial showed a 
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positive association of BP lowering and functional outcome 
irrespective of whether the patient received IVT or not.13 
About bleeding complications after IVT, reports are conflict-
ing where some reported an association between post-throm-
bolysis BP elevation and hemorrhagic transformation, but 
others did not.14–16 The randomized ENCHANTED (Enhanced 
Control of Hypertension and Thrombolysis Stroke Study, BP 
arm) investigating superior efficacy and lower risk of any 
intracerebral hemorrhage of early intensive lowering of BP 
(systolic target 130–140 mm Hg) versus BP control as recom-
mended in guidelines (systolic target <180 mm Hg) is ongo-
ing, and results are anticipated in 2018.17
For several years, stroke neurologists have focused on not 
only standard BP parameters but also BP variability (BPV, 
for review Manning et al18). For the short-term BPV, higher 
BPV was shown to increase the rates of SICH, death, and poor 
outcome after stroke.19–21 Recently, a post hoc analysis of 2 
clinical trials investigating BPV (assessed as SD) showed no 
significant association with 2-week functional dependency 
after stroke and in-hospital mortality.22 More recently, higher 
BPV within 24 hours after stroke was demonstrated to be 
associated with poor prognosis after IVT.13,23
BP management in acute ischemic stroke is relevant for 
clinical practice, but individual strategies are not yet estab-
lished. Here, we determined the influence of BP and BPV 
during the first 24 hours on short- and long-term outcomes 
in a large international cohort of patients who received IVT, 
reflecting the status quo of BP management.
Methods
Study Setting
Acute ischemic stroke patients treated with IVT (Actilyse; Boehringer 
Ingelheim, Germany) and recorded in the Safe Implementation 
of Treatment in Stroke (SITS) international registry between 2002 
and 2013 (https://sitsinternational.org) were considered for analysis 
(n=58 294). Only patients with complete baseline, imaging, outcome, 
and BP measurements (n=28.976; 49.7%) comprised the current 
study sample.24
The SITS registry is an ongoing large international registry pro-
spectively enrolling at 1422 centers in 70 countries. Stroke centers 
contributing to SITS assessed stroke severity with the National 
Institutes of Health Stroke Scale (NIHSS) score. For full details of 
methodology including issues of management about patients data 
including source data and identification, the reader is kindly referred 
to previously published work.24
Definition of BPV
BP values in SITS were documented at least at 3 time points—
pre-treatment, at 2 hours, and at 24 hours after IVT. At each time 
point, there was only 1 BP reading documented. Of these 3 systolic 
BP values, BPV was calculated. As primary measure of variability, 
we choose successive variation (SV) for analysis of BPV (BPV
SV
) 
because it addresses the time sequence in measurements more appro-
priately than other measures.25 SV was calculated as square root of 
average squared difference between 2 successive BP measurements 
















Functional outcome at 3 months was measured by the modified 
Rankin Scale (mRS)—it ranges from 0 to 6. If raters judged 0 or 1, 
excellent functional outcome, and if 0 to 2, good or functional inde-
pendent outcome was concluded.
The primary aim of this study was to investigate the relationship 
of the influence of BPV
SV
 and pre-treatment BP
sys
 on excellent and 
good outcomes after 3 months. In addition, an ordinal analysis of the 
3-month mRS was performed. Recanalization leads to an improve-
ment in early neurological outcome and may likely be associated with 
a drop in BP.26–28 Because the overall number with documented cases 
of recanalization was low (<20%) and this was not the primary aim 
of the study, we chose 2 outcome definitions of early neurological 
improvement (ENI) within 24 hours as a proxy for presumed ves-
sel patency: (1) ENI
20%
 defined as an improvement of ≥20% on the 
NIHSS because this definition was previously demonstrated to be the 
best predictor of functional 3-month outcome and (2) ENI
8
 defined as 
an improvement of ≥8 points on the NIHSS.29–31
Safety measures included the occurrence of SICH after IVT 
according to SITS and ECASS-2 definitions (ECASS-2 [European 
Cooperative Acute Stroke Study 2]; in the online-only Data 
Supplement).
Ethics
Patients within SITS received thrombolysis as standard of care. 
This was a retrospective analysis. Therefore, new ethics review was 
not necessary for data analysis because ethical approvals had been 
obtained in countries where they are required. In other countries, 
SITS was approved as an anonymized register without need for ethi-
cal approval.
Statistical Analysis
For information how the sample was preprocessed—that is, impu-
tation strategies, listwise deletion, and coarsened exact matching—
we kindly refer the reader to the Methods in the online-only Data 
Supplement.
Normally distributed data are presented as mean and SD, non-nor-
mally distributed data as median and interquartile range. For categori-
cal variables, counts and percentages are given. Univariate statistics 




 was primarily used as a continuous variable in all analyses. 
Importantly, BPV
SV
 was categorized for presentation purposes of 





 15–29.9), high (BPV
SV
 30–45), and highest (BPV
SV
 
>45). Associations of covariates and factors on BPV
SV
 were tested 
by Spearman rank, a linear multivariable regression analysis further 
estimated the relevance of each variable in the presence of others. 
Association between BPV
SV
 and 3-month outcome was estimated by 
binomial and ordinal logistic regression. In multivariable regression 
analysis, adjustments were made for age, sex, NIHSS, BP
sys
, history 
of arterial hypertension, history of diabetes mellitus, history of hyper-
cholesterolemia, current smoking, previous stroke, history of atrial 
fibrillation (AF), and history of coronary heart failure.




 on a multiplica-
tive scale and compared the model including the interaction with the 
main model by a likelihood ratio test.32 For main predictors, a 2-sided 
P<0.01 and for interactions terms, a P<0.05 was considered as sta-
tistically significant. For odds ratios and 95% confidence intervals to 
reflect meaningful values (because of the high number of patients), 





a change from the 25th to the 75th percentile. Graphical presentation 




, is on the scale of predicted probabili-
ties using example values of BPV
SV
 (0, 15, 30, 45, and 60) varying 
across all values of BP
sys
.
Statistical analysis was performed with Statistical Package for 
the Social Sciences, SPSS (Released 2012; IBM SPSS Statistics for 
Windows, version 21.0; IBM Corp, Armonk, NY) and R (R Core 
Team 2014. R: A language and environment for statistical comput-
ing. R Foundation for Statistical Computing, Vienna, Austria. http://
www.R-project.org/).
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Sensitivity Analysis
Patients who had AF usually present with higher variability in BP 
readings.33 Therefore, we excluded patients who had known history 
of AF at presentation, testing only non-AF patients for sensitivity 
analysis. This sensitivity analysis should therefore exclude the contri-
bution of the AF population to BPV although we had no information 
on newly diagnosed AF in this data set.
Results
Patients Characteristics According to BPVSV
Of 28 976 patients in the entire cohort, 16 434 patients 
remained after preprocessing. Table 1 shows patients baseline 
characteristics in the entire cohort and the matched cohort. 
BPV
SV
 was categorized into groups (<15, 15–29.9, 30–45, and 
>45) for presentation purposes only reflecting 60.2%, 32.4%, 




 and other covariates were found. 
Best associative strength was found in a positive, moderate cor-
relation of pre-treatment systolic BP (r=0.267; P<0.000001) 
and BPV
SV
. Furthermore, longer stroke onset to treatment times 
(r=0.029; P=0.000001) and higher age (r=0.101; P<0.000001) 
were weakly correlated to higher BPV
SV
, whereas correlation 
between BPV
SV
 and NIHSS (r=−0.013; P=0.024) was hardly 
evident. Patients experiencing higher BPV
SV
 were women and 
had history of hypertension, diabetes mellitus, hypercholesterol-
emia, AF, smoking, and prior stroke (all P<0.01). No association 
was found for patients with history of heart failure (P=0.787).
To further determine which baseline factor would explain 
most of the variance of BPV
SV
, linear multivariable regression 
analysis demonstrated pre-treatment systolic BP to be most 
Table 1. Patients Characteristics and Univariate Outcome in the Entire Cohort, Matched Cohort Including Successive Blood 
Pressure Variability
 
Entire Cohort Matched Cohort Successive Blood Pressure Variability Categories
All (n=28 976) All (n=16 434) <15 (n=9893) 15–29.9 (n=5322) 30–45 (n=988) >45 (n=231)
Patients characteristics
  Age, y, median (IQR, 25–75) 70 (60–77) 71 (63–77) 71 (63–77) 71 (63–77) 73 (65–77) 73 (66–78)
  Baseline NIHSS, median (IQR, 25–75) 11 (7–17) 11 (7–16) 11 (7–16) 11 (7–16) 12 (7–17) 12 (7–16)
  Onset to treatment time, min 147 (119–175) 145 (120–170) 145 (120–170) 146 (120–170) 145 (120–170) 150 (120–174)
  Pre-treatment systolic blood pressure 150 (136–167) 155 (140–168) 155 (140–168) 156 (141–169) 157 (141–170) 160 (140–173)
  Sex, female, n (%) 12373 (42.7) 6625 (40.3) 3950 (39.9) 2150 (40.4) 427 (43.2) 98 (42.4)
  History of arterial hypertension, n (%) 18309 (63.2) 11455 (69.7) 6880 (69.5) 3651 (68.6) 738 (74.7) 186 (80.5)
  History of diabetes mellitus, n (%) 4899 (16.9) 1809 (11) 1080 (10.9) 566 (10.6) 128 (13) 35 (15.2)
  History of hypercholesterolemia, n (%) 9825 (33.9) 5706 (34.7) 3356 (33.9) 1919 (36.1) 362 (36.6) 69 (29.9)
  History of active smoking, n (%) 6197 (21.4) 3364 (20.5) 1998 (20.2) 1135 (21.3) 184 (18.6) 47 (20.3)
  Prior stroke, n (%) 3617 (12.5) 2157 (13.1) 1287 (13) 655 (12.3) 178 (18) 37 (16)
  History of atrial fibrillation, n (%) 6641 (22.9) 3975 (24.2) 2338 (23.6) 1316 (24.7) 247 (25) 74 (32)
  History of coronary heart failure, n (%) 2422 (8.4) 1304 (7.9) 747 (7.6) 444 (8.3) 89 (9) 24 (10.4)
Outcome definitions
  Symptomatic Intracerebral hemorrhage       
   SITS definition, n (%) 412 (1.4) 272 (1.7) 144 (1.5) 96 (1.8) 23 (2.3) 9 (3.9)
   ECASS-2 definition, n (%) 1322 (4.6) 755 (4.6) 426 (4.3) 244 (4.6) 64 (6.5) 21 (9.1)
Modified Rankin Scale at 90 d, n (%)
   0 6602 (22.8) 3732 (22.7) 2264 (22.9) 1209 (22.7) 214 (21.7) 45 (19.5)
   1 6088 (21) 3570 (21.7) 2151 (21.7) 1200 (22.5) 181 (18.3) 38 (16.5)
   2 4567 (15.8) 2660 (16.2) 1631 (16.5) 853 (16) 146 (14.8) 30 (13)
   3 3729 (12.9) 2106 (12.8) 1264 (12.8) 682 (12.8) 124 (12.6) 36 (15.6)
   4 3239 (11.2) 1879 (11.4) 1131 (11.4) 589 (11.1) 123 (12.4) 36 (15.6)
   5 1418 (4.9) 763 (4.6) 439 (4.4) 252 (4.7) 59 (6) 13 (5.6)
   6 3333 (11.5) 1724 (10.5) 1013 (10.2) 537 (10.1) 141 (14.3) 33 (14.3)
  Early neurological improvement <24 h       
   8 points less on NIHSS 6411 (22.1) 3533 (21.5) 2078 (21) 1193 (22.4) 220 (22.3) 42 (18.2)
   20% less on NIHSS 18786 (64.8) 10805 (65.7) 6490 (65.6) 3577 (67.2) 607 (61.4) 131 (56.7)
ECASS-2 indicates European Cooperative Acute Stroke Study 2; NIHSS, National Institutes of Health Stroke Scale; and SITS, Safe Implementation of Treatment in Stroke.
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influential (5.55% explained variance), followed by age (1.18% 
explained variance). Interestingly, patients with history of hyper-
tension were only marginally predictive for higher BPV
SV
 (0.2% 
explained variance). All other variables also explained <1% vari-
ance leaving 92% of the variance in BPV unexplained (Figure 1).
Outcome Analysis According to BPVSV
Early Neurological Improvement
About short-term outcome, univariate analysis of BPV
SV
 was 
not significantly associated with ENI
20%
 (P=0.428) and ENI
8
 
(P=0.394). Adjustment with relevant confounders in multi-
variable analysis did not change this result (Table 2).
Three-Month Outcome
Excellent outcome was not significantly associated with 
BPV
SV
 by means of univariate (P=0.346) and multivariable 
(Table 2) adjustments.
Functional independency was less likely in patients with 
higher BPV
SV
 by means of univariate (P=0.021) and multi-
variable regression (Table 2) analyses.
A shift to the next higher (worse) mRS category (categori-
cal shift) was more likely in patients with higher BPV
SV
 in 
multivariable regression analysis (Table 2).
Mortality within 90 days after stroke was more likely 
in patients who experienced higher BPV
SV
 (univariable, 
P=0.004; multivariable, Table 2).
Symptomatic Intracerebral Hemorrhage
In terms of safety, BPV
SV
 was associated with the presence of 
SICH
SITS
 (P=0.0001) and SICH
ECASS
 (P=0.0017). Adjustment 
in multivariable analysis reinforced these results irrespective 
of the bleeding definition used (Table 2).




 was significantly associated with lower odds 
ratios for ENI, lower rates of favorable outcome at 3 months, 
and higher risk of SICH in multivariable analysis. No associa-
tion with mortality was found (Table 2).
BPVSV and Pre-Treatment BPsys 
Interaction (BPVSV-by-BPsys)
Determining outcome across the mRS at different levels of 
BPV
SV
 and across the range of BP
sys
 revealed an X-shaped 




 interaction was found 
for outcomes of ENI
20%
 but not for ENI
8
 for excellent and 
good functional outcome as well as for the shift analysis of 
the mRS. This relationship was not obvious for mortality and 
safety (Table 3).
Sensitivity Analysis of BPVSV-by-BPsys Interaction 
in Patients Presenting With No History of AF





their interaction was largely unchanged and is shown in Tables 
I and II in the online-only Data Supplement.
Discussion
In this study with a large cohort of ischemic stroke patients 
treated with IVT, we highlight the prognostic significance 
of successive BPV
SV
 for functional outcome after stroke and 
especially for safety. A novel finding in our study is the better 
prediction of short- and long-term functional outcomes when 
considering the reciprocal interaction of pre-treatment BP 
(BP
sys
 high, medium, or low) and the course of BP 24-hour 
post-thrombolysis (accounted by BPV
SV
).
BPV in our study was associated with several definitions of 
functional outcome and safety. Importantly, these results were 
independent of BP
sys
 (a well-known predictor of safety15,16 and 
functional outcome after stroke4,6,8,13,34). A post hoc analysis 
from IST-3 (The Third International Stroke Trial) reported an 
association of higher BPV with adverse events, the occurrence 
of SICH and poor 6-month outcome.13 Our results may com-
plement those in so far that we found short-term BPV to be of 
significance for safety (SICH) and several long-term outcome 
definitions. About short-term outcome (2-week outcome and 
in-hospital outcome), 2 most recent studies did not find any 
importance of BPV in outcome prediction.22,23 Our results sup-
port these studies for the most part because we found no clear 






The overall comparability of those studies with ours is nar-
row because of smaller sample sizes, different acquisition of 
BP intervals, and various definitions of BPV and outcomes.





) being relevant to several issues, we put both in context 
by analyzing whether patients with a particular pre-treatment BP 
would yield different functional outcomes with various degrees 
of BPV (Figure 2A and 2B). For patients who presented with 
normal BP
sys
, neither high nor low BPV
SV
 seemed to influence 
the outcome in some way or other. However, patients present-
ing with low BP
sys
 seemed to benefit from low BPV
SV
. Equally 
did patients with high pre-treatment BP
sys







) seems, for example, 
when physicians actively intervene on high BP
sys
 but may also 
be attributed to the natural BP course after stroke—the trend 
of BP to decline over time. In this regard, the post hoc analy-
sis of IST-3 suggested similarly a good outcome at 6 months 
after stroke when BP lowering was more intense during the 
first 24 hours,13 whereas other studies did not.9–12,35 In patients 
in whom pre-treatment BP
sys
 is within the normal range, physi-
cians usually restrain active elevation of BP (resulting in low 
BPV
SV
). The combination of high BP
sys
 and low BPV
SV
 seems 
Figure 1. Baseline factors explaining successive blood pressure 
variability. IVT indicates intravenous thrombolysis; and NIHSS, 
National Institutes of Health Stroke Scale.
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unfavorable, most probably because BP
sys
 remains too high 
because of lack of extrinsic or intrinsic modulation or because 
of insufficient response to possible interventions. An equally 
unfavorable combination seems to be low BP
sys
 and high BPV
SV
 
that might be explainable by exceedingly BP lowering leading 
to cerebral hypoperfusion or vice versa unstable conditions and 
the need for interventional elevation of BP.
Overall, these results indirectly indicate that patients 
may benefit from BP management that is personalized. This 
hypothesis could (at least partially) explain inconsistencies 
in several observational studies on BP lowering, where some 
suggested much lower absolute BP
sys
 values to be favorable 
(range between 140 and 150 mmHg).4,6,8 In contrast, several 
post hoc analyses of randomized clinical trials reported no 
advantage.9–12,35 The BP arm of the ENCHANTED trial is 
still ongoing, possibly the results will offer insights about the 
importance of BP lowering in thrombolyzed patients.17
Certainly, BP management in the acute phase of stroke 
should include aspects of the presence of penumbra, presence 
of vessel occlusion, collateral flow, revascularization status, 
Table 2. Adjusted Influence of Pre-Treatment Systolic Blood Pressure and Successive Blood Pressure 
Variability on Outcomes of Short-Term, Safety, and Long-Term Outcome
 
Successive Blood Pressure 
Variability Odds Ratio (95% 
Confidence Interval)*
P Value
Pre-Treatment Systolic Blood 




  Early neurological improvement (NIHSS 
improvement 20%)
0.96 (0.93–1.00) 0.069 0.86 (0.82–0.90) <0.0001
  Early neurological improvement (NIHSS 8-point) 1.01 (0.96–1.06) 0.737 0.87 (0.82–0.92) <0.0001
Outcome 90 d after stroke
  Excellent (mRS score of 0–1) 0.98 (0.94–1.02) 0.239 0.84 (0.80–0.89) <0.0001
  Functional independent (mRS score of 0–2) 0.94 (0.90–0.98) 0.002 0.89 (0.84–0.93) <0.0001
  Ordinal shift mRS (shift to next higher [worse] 
category)
1.04 (1.01–1.08) 0.014 1.14 (1.10–1.19) 0.014
  Death (mRS score of 6) 1.10 (1.03–1.16) 0.002 1.06 (0.98–1.15) 0.135
Symptomatic intracerebral hemorrhage
  SITS definition 1.24 (1.10–1.40) 0.0003 1.24 (1.03–1.48) 0.02
  ECASS-2 definition 1.14 (1.06–1.23) 0.0009 1.20 (1.08–1.34) 0.001
Adjusted for age, sex, baseline NIHSS, history of arterial hypertension, history of diabetes mellitus, history of hypercholesterolemia, history 
of smoking, history of atrial fibrillation, history of coronary heart failure, and prior stroke. ECASS-2 indicates European Cooperative Acute 
Stroke Study 2; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; and SITS, Safe Implementation of Treatment 
in Stroke.
*Indicating a 12-point change in blood pressure variability (=change from 25th percentile to 75th percentile).
†Indicating a 25-point change in systolic blood pressure (=change from 25th percentile to 75th percentile).
Figure 2. Relationship of pre-treatment systolic blood pressure (BP) and successive BP variability (BPV) influencing functional outcome. 
A, Probability of reaching modified Rankin Scale (mRS) category by range of pre-treatment systolic blood pressures; given are example 
categories of successive blood pressure variability (no=0, low=15, med=30, high=45, highest=60). B, Probability of good functional out-
come (mRS score of 0–2) for conditioned values of successive BPV (0, 15, 30, 45, and 60).
1832  Stroke  July 2017
and stroke cause.36 Although our analysis falls short to address 
these individual aspects because of its retrospective design, 
we interpret our findings a step toward a better understanding 
of BP and BPV in acute stroke.
The authors may also point toward a better understanding 
of variability as BP characteristic (see Manning Stroke 2015 
for review18). In observational studies, where BP manage-
ment is not actively monitored, it is unclear what we exactly 
measure when we measure BPV. BPV is under the influence 
of numerous extrinsic (administered and preexisting medica-
tion, arrhythmia requiring β-blocker, vegetative and emotional 
stressors, and positional [eg, lying versus upright] and con-
tinuous recording versus manual measurement) and intrinsic 
(arterial hypertension, fluid balance, stroke subtype, recanali-
zation, and autonomic regulation or dysregulation) factors.37,38 
Even so, attempts to explain BPV in the multivariable analysis 
by all available patients baseline characteristics left 92% vari-
ance unexplained in our study.
Interestingly, BP
sys
 was the strongest predictor for BPV. As 
for some definitions of BPV, this could easily be explainable 
because pre-treatment BP
sys
 influences, for example, SD to a 
certain extent (depending on the number of available BP read-
ings). Therefore, we considered a similar type of influence for 
the variability measure chosen in this study (successive BP 
variability). In the SITS International Thrombolysis registry, 
BP is documented at only 3 time points. This is because to 
minimize the workload of the investigator because the SITS 
IVT protocol has ≈200 other variables. The individual centers 
were not required to standardize their protocol when measur-
ing BP—both facts that might lead to bias in interpretation of 
BP and BPV. In routine clinical practice, BP is measured at 
least hourly after IVT up until follow-up imaging, but unfortu-
nately these additional data are not available in the SITS reg-
istry. However, as shown in the online-only Data Supplement, 
we demonstrate that the variability formula of BPV
SV
 is less 
prone to single values.25 This also improves plausibility that 




 interaction is not explainable 
as a by-product of the chosen BPV definition.
Besides the main limitation of uncontrolled data and ret-
rospective analysis, our study has additional limitations. 
Although we demonstrated no influence of NIHSS or other 
baseline factors on BPV in linear regression, BPV may still be 
an epiphenomenon of clinical parameters, for example, sever-
ity of stroke, lesion growth (as demonstrated by Delgado-
Mederos et al39), or BP lowering interventions. We present an 
effect of the interaction between BP and BPV for the whole 
cohort and for those patients without AF, but most likely, there 
were subgroups of patients (different stroke causes, presence 
of penumbra, vessel occlusion, recanalization status, and col-
lateral flow) for whom this interaction might be more or less 
relevant. None of these factors was investigated in a well-
structured way with respect to BPV.
Because of the retrospective design of this study, we were 
not able to control neither for a single nor much less for all 
of those variables. Only about a half of all patients registered 
in SITS were further analyzed, and after preprocessing, only 
16 434 patients (28%) remained; this is an important limita-
tion of the study. Matching may reduce overall degree of bias; 
however, it has to be stressed that control of unobserved vari-
ables—as in randomized trials—is not possible.
Despite these limitations, we interpret our findings as novel 
and significant with implications for patient care and future 
studies. The main strength of our study is that it comprises 
by far the largest cohort of IVT-treated patients in whom this 
analysis has been completed.
Conclusions
BP variability during 24 hours after thrombolysis is of sig-
nificant but currently under investigated relevance for stroke 
outcome. Putting the course of BP 24 hours post-thrombolysis 
in relation to its pre-treatment value significantly improved 
the prediction of specific short- and long-term outcomes of 
stroke in this study. Thus, future clinical trials should carefully 
consider both—pre-treatment BP and its variability over time.
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